Hims & Hers Health announced Wednesday it will offer generic semaglutide in Canada as Novo Nordisk's patent on its branded drugs Ozempic and Wegovy is set to expire in January
Trial registrations ClinicalTrials.gov identifiers: NCT02054897, NCT01930188, NCT01885208, NCT02128932, NCT02305381, NCT01720446, NCT02207374, NCT02254291, NCT02906930, NCT02863328, NCT02607865, NCT02863419, NCT02827708, NCT02692716, NCT02849080, NCT03021187, NCT03018028, NCT03015220
This stimulates renewal within the skin, bringing new, healthy skin to the surface
Patient safety guidance should include: Education about expected appetite changes and strategies for maintaining adequate nutrition Monitoring for excessive weight loss or signs of malnutrition Assessment of mental health at follow-up visits Clear instructions to report severe or persistent nausea, vomiting, or neuropsychiatric symptoms Awareness that cognitive effects remain investigational and should not influence prescribing decisions Reporting severe persistent abdominal pain (pancreatitis), right upper quadrant pain/jaundice (gallbladder disease), severe abdominal distension with inability to pass gas or stool (possible ileus), persistent vomiting or signs of dehydration, and new/worsening vision changes (retinopathy) Understanding increased hypoglycemia risk when combined with insulin or sulfonylureas GLP-1 receptor agonists are contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2, and should be used with caution in patients with severe gastrointestinal disease, including gastroparesis
Melanotan II is a synthetic peptide developed to stimulate the production of melanin in the body, mimicking the action of the naturally occurring hormone alpha-melanocyte-stimulating hormone (-MSH)
